Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors.
Benign prostatic hypertrophy (BPH) and its associated lower urinary-tract symptoms (LUTS) commonly result in a significant decrease in the quality of life (QOL) of aging men. Although several safe and effective medications are currently available for the management of this disease, newly emerging research has focused on the exploration of unconventional pharmacological therapy. In particular, multiple clinical trials published within the past two years have explored the use of phosphodiesterase-5 (PDE-5) inhibitors for the alleviation of LUTS secondary to BPH. Although this class of medication has traditionally been used in men with erectile dysfunction (ED), the preliminary results from these studies have offered promising evidence for use of PDE-5 inhibitors in BPH.
Govonlu
Sara
S
CVS Pharmacy, Needham, Massachusetts. USA.
Wooding
Fae G
FG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors